Major coronary artery anomalies in a pediatric population: incidence and clinical importance. J Am Coll Cardiol. 2001;37:593 7. S5.5-9. Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. 2016;374:2441 52. S5.5-10. Smallman DP, Webber BJ, Mazuchowski EL, et al. Sudden cardiac death associated with physical exertion in the US military, 2005 2010. BJ Sports Med. 2016;50:118 23. S5.5-11. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young com- petitive athletes: analysis of 1866 deaths in the United States, 1980 2006. Circulation. 2009;119:1085 92. S5.5-12. Krasuski RA, Magyar D, Hart S, et al. Long-term outcome and impact of surgery on adults with coronary arteries originating from the opposite coronary cusp. Circulation. 2011;123:154 62. S5.5-13. Layser RB, Savage MP, Halpern EJ. Anomalous coronary arteries: analysis of clinical outcome based upon arterial course and surgical intervention in an adult population. Acad Radiol. 2016;23:1015 23. S5.5-14. Taylor AJ, Rogan KM, Virmani R. Sudden cardiac death associ- ated with isolated congenital coronary artery anomalies. J Am Coll Cardiol. 1992;20:640 7. 5.5.1. Surgery for Arrhythmia Management S5.5.1-1. Anter E, Hutchinson MD, Deo R, et al. Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopa- thy. Circ Arrhythm Electrophysiol. 2011;4:494 500. S5.5.1-2. Bhavani SS, Tchou P, Saliba W, et al. Surgical options for refractory ventricular tachycardia. J Card Surg. 2007;22:533 4. S5.5.1-3. Choi EK, Nagashima K, Lin KY, et al. Surgical cryoablation for ven- tricular tachyarrhythmia arising from the left ventricular outflow tract region. Heart Rhythm. 2015;12:1128 36. S5.5.1-4. Kumar S, Barbhaiya CR, Sobieszczyk P, et al. Role of alternative interventional procedures when endo- and epicardial catheter ablation attempts for ventricular arrhythmias fail. Circ Arrhythm Electrophysiol. 2015;8:606 15. S5.5.1-5. Mulloy DP, Bhamidipati CM, Stone ML, et al. Cryoablation dur- ing left ventricular assist device implantation reduces postop- erative ventricular tachyarrhythmias. J Thorac Cardiovasc Surg. 2013;145:1207 13. S5.5.1-6. Patel M, Rojas F, Shabari FR, et al. Safety and feasibility of open chest epicardial mapping and ablation of ventricular tachycardia during the period of left ventricular assist device implantation. J Cardiovasc Electrophysiol. 2016;27:95 101. S5.5.1-7. Sartipy U, Albage A, Straat E, et al. Surgery for ventricular tachycar- dia in patients undergoing left ventricular reconstruction by the Dor procedure. Ann Thorac Surg. 2006;81:65 71. CLINICAL STATEMENTS AND GUIDELINES 5.6. Autonomic Modulation S5.6-1. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of ateno- lol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144:e10. S5.6-2. Vaseghi M, Barwad P, Malavassi Corrales FJ, et al. Cardiac sympa- thetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol. 2017;69:3070 80. S5.6-3. Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denerva- tion in patients with refractory ventricular arrhythmias or electri- cal storm: intermediate and long-term follow-up. Heart Rhythm. 2014;11:360 6. S5.6-4. Schwartz PJ, Motolese M, Pollavini G. Prevention of sudden car- diac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol. 1992;3:2 16. S5.6-5. Shen MJ, Zipes DP. Role of the autonomic nervous system in modu- lating cardiac arrhythmias. Circ Res. 2014;114:1004 21. S5.6-6. Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympa- thetic denervation for the management of electrical storm. J Am Coll Cardiol. 2012;59:91 2. 6. ACUTE MANAGEMENT OF SPECIFIC VA S6-1. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guide- lines update for cardiopulmonary resuscitation and emergency car- diovascular care. Circulation. 2015;132 suppl 2:S444 64. S6-2. Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004;351:647 56. S6-3. Sasson C, Rogers MA, Dahl J, et al. Predictors of survival from out- of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2010;3:63 81. S6-4. Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884 90. S6-5. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; 1711 22. S6-6. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resusci- tation after out-of-hospital cardiac arrest due to ventricular fibrilla- tion. N Engl J Med. 1999;341:871 8. S6-7. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med. 1997;336:1629 33. S6-8. Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percuta- neous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation. Crit Care. 2011;15:R122. S6-9. Zanuttini D, Armellini I, Nucifora G, et al. Impact of emergency coro- nary angiography on in-hospital outcome of unconscious survivors after out-of-hospital cardiac arrest. Am J Cardiol. 2012;110:1723 8. S6-10. Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac arrest patients without ST-segment elevation pattern: insights from the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011 8. S6-11. Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procain- amide and lidocaine in terminating sustained monomorphic ven- tricular tachycardia. Am J Cardiol. 1996;78:43 6. S6-12. Markel DT, Gold LS, Allen J, et al. Procainamide and survival in ven- tricular fibrillation out-of-hospital cardiac arrest. Acad Emerg Med. 2010;17:617 23. S6-13. Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intra- venous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38:1329 35. S6-14. Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hos- pital ventricular fibrillation. Does it improve survival? Resuscitation. 1997;33:199 205. S6-15. Kudenchuk PJ, Newell C, White L, et al. Prophylactic lidocaine for post resuscitation care of patients with out-of-hospital ventricular fibrillation cardiac arrest. Resuscitation. 2013;84:1512 8. S6-16. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. 1993;270:1589 95. S6-17. Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102:742 7. S6-18. Piccini JP, Hranitzky PM, Kilaru R, et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventric- ular tachycardia and ventricular fibrillation following acute myocar- dial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol. 2008;102:1427 32. S6-19. Callaham M, Madsen CD, Barton CW, et al. A randomized clinical trial of high-dose epinephrine and norepinephrine vs standard-dose epinephrine in prehospital cardiac arrest. JAMA. 1992;268:2667 72. S6-20. Donnino MW, Salciccioli JD, Howell MD, et al. Time to adminis- tration of epinephrine and outcome after in-hospital cardiac arrest with non-shockable rhythms: retrospective analysis of large in-hos- pital data registry. BMJ. 2014;348:g3028. S6-21. Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med. 1998;339:1595 601. S6-22. Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA. 2012;307:1161 8. S6-23. Jacobs IG, Finn JC, Jelinek GA, et al. Effect of adrenaline on sur- vival in out-of-hospital cardiac arrest: a randomised double-blind placebo-controlled trial. Resuscitation. 2011;82:1138 43. S6-24. Koscik C, Pinawin A, McGovern H, et al. Rapid epinephrine admin- istration improves early outcomes in out-of-hospital cardiac arrest. Resuscitation. 2013;84:915 20. S6-25. Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of ligno- caine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994;344:18 23. S6-26. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine ver- sus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002;90:853 9. S6-27. Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibril- lation. Emerg Med J. 2002;19:57 62. S6-28. Thel MC, Armstrong AL, McNulty SE, et al. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet. 1997;350:1272 6. S6-29. Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur Heart J. 2000;21:198 205. S6-30. Belhassen B, Horowitz LN. Use of intravenous verapamil for ven- tricular tachycardia. Am J Cardiol. 1984;54:1131 3. S6-31. Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intrave- nous verapamil for sustained ventricular tachycardia. Am J Cardiol. 1987;59:1107 10. S6-32. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide- lines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:e385 484. S6-33. Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopul- monary resuscitation prior to defibrillation in patients with out-of- hospital ventricular fibrillation. JAMA. 1999;281:1182 8. S6-34. Cobb LA, Weaver WD, Fahrenbruch CE, et al. Community-based interventions for sudden cardiac death. Impact, limitations, and changes. Circulation. 1992;85 suppl:I98 I102. S6-35. Weisfeldt ML, Becker LB, Resuscitation after cardiac arrest: a 3-phase time-sensitive model. JAMA. 2002;288:3035 8. S6-36. Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ven- tricular fibrillation: a randomized trial. JAMA. 2003;289:1389 95. S6-37. Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardio- vascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122 suppl 2:S729 67. CLINICAL STATEMENTS AND GUIDELINES S6-38. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention tri- als. AVID, CASH and CIDS studies. Antiarrhythmics vs implant- able defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071 8. S6-39. Kern KB. Optimal treatment of patients surviving out-of-hospital cardiac arrest. JACC Cardiovasc Intervent. 2012;5:597 605. S6-40. Perkins GD, Jacobs IG, Nadkarni VM, et al. Cardiac arrest and car- diopulmonary resuscitation outcome reports: update of the Utstein Resuscitation Registry Templates for out-of-hospital cardiac arrest: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian and New Zealand Council on Resuscitation, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Southern Africa, Resuscitation Council of Asia); and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Circulation. 2015;132:1286 300. S6-41. Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualifica- tion recommendations for competitive athletes with cardiovascular abnormalities: Task Force 12: emergency action plans, resuscitation, cardiopulmonary resuscitation, and automated external defibrilla- tors: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e334 8. S6-42. Joglar JA, Page RL. Out-of-hospital cardiac arrest are drugs ever the answer? N Engl J Med. 2016;374:1781 2. 7. ONGOING MANAGEMENT OF VA AND SCD RISK RELATED TO SPECIFIC DISEASE STATES 7.1. Ischemic Heart Disease 7.1.1. Secondary Prevention of SCD in Patients With Ischemic Heart Disease S7.1.1-1. The AVID Investigators. A comparison of antiarrhythmic-drug ther- apy with implantable defibrillators in patients resuscitated from near- fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576 83. S7.1.1-2. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implant- able cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297 302. S7.1.1-3. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary preven- tion trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21: 2071 8. S7.1.1-4. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748 54. S7.1.1-5. Raitt MH, Renfroe EG, Epstein AE, et al. Stable ventricular tachycardia is not a benign rhythm: insights from the antiarrhyth- mics versus implantable defibrillators (AVID) registry. Circulation. 2001;103:244 52. S7.1.1-6. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratifi- cation on cost-effectiveness of the implantable cardioverter defibril- lator. Am Heart J. 2002;144:440 8. S7.1.1-7. Bass EB, Elson JJ, Fogoros RN, et al. Long-term prognosis of patients undergoing electrophysiologic studies for syncope of unknown ori- gin. Am J Cardiol. 1988;62:1186 91. S7.1.1-8. Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ven- tricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol. 2001;38:1718 24. S7.1.1-9. Maury P, Baratto F, Zeppenfeld K, et al. Radio-frequency ablation as primary management of well-tolerated sustained monomor- phic ventricular tachycardia in patients with structural heart dis- ease and left ventricular ejection fraction over 30%. Eur Heart J. 2014;35:1479 85. S7.1.1-10. Pauriah M, Cismaru G, Magnin-Poull I, et al. A stepwise approach to the management of postinfarct ventricular tachycardia using catheter ablation as the first-line treatment: a single-center expe- rience. Circ Arrhythm Electrophysiol. 2013;6:351 6. S7.1.1-11. Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiar- rhythmic drugs in survivors of serious ventricular tachyar- rhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002;105:2049 57. S7.1.1-12. O Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103:1416 21. S7.1.1-13. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effec- tiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10:iii iv, ix xi, 1 164 S7.1.1-14. Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost- effectiveness of implantable cardioverter defibrillators in the treat- ment of ventricular arrhythmias among medicare beneficiaries. Am J Med. 2002;112:519 27. S7.1.1-15. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. 7.1.1.1. Coronary Artery Spasm S7.1.1.1-1. Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients. J Am Coll Cardiol. 1998;31:57 61. S7.1.1.1-2. Myerburg RJ, Kessler KM, Mallon SM, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial isch- emia due to coronary-artery spasm. N Engl J Med. 1992;326: 1451 5. S7.1.1.1-3. Ahn JM, Lee KH, Yoo SY, et al. Prognosis of variant angina manifesting as aborted sudden cardiac death. J Am Coll Cardiol. 2016;68:137 45. S7.1.1.1-4. Matsue Y, Suzuki M, Nishizaki M, et al. Clinical implications of an implantable cardioverter-defibrillator in patients with vasospas- tic angina and lethal ventricular arrhythmia. J Am Coll Cardiol. 2012;60:908 13. S7.1.1.1-5. Takagi Y, Yasuda S, Tsunoda R, et al. Clinical characteristics and long-term prognosis of vasospastic angina patients who sur- vived out-of-hospital cardiac arrest: multicenter registry study of the Japanese Coronary Spasm Association. Circ Arrhythm Electrophysiol. 2011;4:295 302. S7.1.1.1-6. Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implant- able cardioverter-defibrillators in refractory variant angina pectoris complicated by ventricular fibrillation in patients with angiograph- ically normal coronary arteries. Am J Cardiol. 2002;89:1114 6. S7.1.1.1-7. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008). Circ J. 2010;74:1745 62. S7.1.1.1-8. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344 426. S7.1.1.1-9. Morikawa Y, Mizuno Y, Yasue H. Letter by Morikawa et al regard- ing article, coronary artery spasm: a 2009 update. Circulation. 2010;121:e16. S7.1.1.1-10. Sasaki S, Tomita H, Shibutani S, et al. Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circ J. 2014;78:2987 9. 7.1.1.2. Post CABG VT/VF S7.1.1.2-1. Ascione R, Reeves BC, Santo K, et al. Predictors of new malig- nant ventricular arrhythmias after coronary surgery: a case-control study. J Am Coll Cardiol. 2004;43:1630 8. CLINICAL STATEMENTS AND GUIDELINES S7.1.1.2-2. Saxon LA, Wiener I, Natterson PD, et al. Monomorphic versus poly- morphic ventricular tachycardia after coronary artery bypass graft- ing. Am J Cardiol. 1995;75:403 5. S7.1.1.2-3. Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventric- ular tachycardia after cardiac surgery. Circulation. 1999;99:903 8. S7.1.1.2-4. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary- artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569 75. S7.1.1.2-5. Vakil K, Florea V, Koene R, et al. Effect of coronary artery bypass grafting on left ventricular ejection fraction in men eli- gible for implantable cardioverter-defibrillator. Am J Cardiol. 2016;117:957 60. S7.1.1.2-6. Mittal S, Lomnitz DJ, Mirchandani S, et al. Prognostic significance of nonsustained ventricular tachycardia after revascularization. J Cardiovasc Electrophysiol. 2002;13:342 6. S7.1.1.2-7. Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defi- brillator. Circ Arrhythm Electrophysiol. 2013;6:117 28. 7.1.2. Primary Prevention of SCD in Patients With Ischemic Heart Disease S7.1.2-1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S7.1.2-2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877 83. S7.1.2-3. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933 40. S7.1.2-4. Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk strati- fication on cost-effectiveness of the implantable cardioverter defi- brillator. Am Heart J. 2002;144:440 8. S7.1.2-5. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the pre- vention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882 90. S7.1.2-6. Cantero-P rez EM, Sobrino-M rquez JM, Grande-Trillo A, et al. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart trans- plantation. Transplant Proc. 2013;45:3659 61. S7.1.2-7. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158 65. S7.1.2-8. Gandjbakhch E, Rovani M, Varnous S, et al. Implantable cardio- verter-defibrillators in end-stage heart failure patients listed for heart transplantation: results from a large retrospective registry. Arch Cardiovasc Dis. 2016;109:476 85. S7.1.2-9. Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardio- verter-defibrillators on waitlist mortality among patients await- ing heart transplantation: an UNOS/OPTN analysis. JACC Clin Electrophysiol. 2017;3:33 40. S7.1.2-10. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarc- tion. N Engl J Med. 2004;351:2481 8. S7.1.2-11. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427 36. S7.1.2-12. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97:2129 35. S7.1.2-13. Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:2310 8. S7.1.2-14. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defi- brillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD- HeFT). Circulation. 2006;114:135 42. S7.1.2-15. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and eco- nomic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142:593 600. S7.1.2-16. Buxton AE, Calkins H, Callans DJ, et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards. Circulation. 2006;114:2534 70. S7.1.2-17. Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effec- tiveness of prophylactic implantation of a cardioverter defibril- lator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11:716 26. S7.1.2-18. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implant- able cardioverter-defibrillators. N Engl J Med. 2005;353:1471 80. S7.1.2-19. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of pri- mary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. Eur Heart J. 2013;34:211 9. S7.1.2-20. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. S7.1.2-21. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic test- ing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000;342:1937 45. S7.1.2-22. Zaman S, Sivagangabalan G, Narayan A, et al. Outcomes of early risk stratification and targeted implantable cardioverter-defibrilla- tor implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Circulation. 2009;120:194 200. S7.1.2-23. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140 50. S7.1.2-24. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defi- brillator therapy in patients who are not included or not well rep- resented in clinical trials. Circulation. 2014;130:94 125. 7.1.3. Treatment and Prevention of Recurrent VA in Patients With Ischemic Heart Disease S7.1.3-1. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta- blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165 71. S7.1.3-2. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implant- able-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. 1999;340:1855 62. S7.1.3-3. Kettering K, Mewis C, Dornberger V, et al. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricu- lar tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2002;25:1571 6. S7.1.3-4. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia abla- tion versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111 21. S7.1.3-5. Mallidi J, Nadkarni GN, Berger RD, et al. Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ven- tricular tachycardia in patients with structural heart disease. Heart Rhythm. 2011;8:503 10. S7.1.3-6. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricu- lar tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol. 2016;67:674 83. S7.1.3-7. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation. 2008;118:2773 82. S7.1.3-8. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recur- rent scar-related ventricular tachycardia using electroanatomical CLINICAL STATEMENTS AND GUIDELINES mapping and irrigated ablation technology: results of the pro- spective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2010;21:47 53. S7.1.3-9. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997 2007. S7.1.3-10. Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol. 2015;26:151 7. S7.1.3-11. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre ran- domised controlled trial. Lancet. 2010;375:31 40. S7.1.3-12. Sesselberg HW, Moss AJ, McNitt S, et al. Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. Heart Rhythm. 2007;4:1395 402. S7.1.3-13. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781 8. S7.1.3-14. Sears SF Jr, Todaro JF, Lewis TS, et al. Examining the psychoso- cial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999;22:481 9. S7.1.3-15. Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventric- ular tachycardia after cardiac surgery. Circulation. 1999;99:903 8. S7.1.3-16. Brugada J, Aguinaga L, Mont L, et al. Coronary artery revasculariza- tion in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol. 2001;37:529 33. S7.1.3-17. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar- macological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015;12:CD008093. S7.1.3-18. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ven- tricular tachycardia burden and ICD shocks in patients with drug- refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600 6. S7.1.3-19. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250 9. S7.1.3-20. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77 82. S7.1.3-21. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992;327:227 33. S7.1.3-22. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748 54. S7.1.3-23. Sears SE Jr, Conti JB, Understanding implantable cardioverter defi- brillator shocks and storms: medical and psychosocial consider- ations for research and clinical care. Clin Cardiol. 2003;26:107 11. S7.1.3-24. Sweeney MO, Sherfesee L, Degroot PJ, et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7:353 60. S7.1.3-25. Berntsen RF, Gunnes P, Lie M, et al. Surgical revascularization in the treatment of ventricular tachycardia and fibrillation exposed by exercise-induced ischaemia. Eur Heart J. 1993;14:1297 303. S7.1.3-26. Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/ SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythm. 2016;32:1 28. 7.2. Nonischemic Cardiomyopathy S7.2-1. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501 11. S7.2-2. Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhance- ment on cardiac magnetic resonance predicts adverse cardiovascu- lar outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7:250 8. S7.2-3. Piers SR, Tao Q, van Huls van Taxis CF, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875 83. S7.2-4. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consen- sus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partner- ship between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13:1077 109. S7.2-5. Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med. 2010;12:655 67. S7.2-6. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016. 2017;10:411 20. S7.2-7. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.2-8. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol. 2016;68:2299 307. S7.2-9. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud- den death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209 10. S7.2-10. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250 60. S7.2-11. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79 83. S7.2-12. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493 500. 7.2.1. Secondary Prevention of SCD in Patients With NICM S7.2.1-1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576 83. S7.2.1-2. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implant- able cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297 302. S7.2.1-3. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardio- myopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874 9. S7.2.1-4. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748 54. S7.2.1-5. Raitt MH, Renfroe EG, Epstein AE, et al. Stable ventricular tachy- cardia is not a benign rhythm: insights from the Antiarrhythmics versus Implantable Defibrillators (AVID) registry. Circulation. 2001;103:244 52. S7.2.1-6. Brilakis ES, Shen WK, Hammill SC, et al. Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol. 2001;24:1623 30. S7.2.1-7. Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol. 2000;85:981 5. S7.2.1-8. Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonisch- emic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol. 1999;33:1964 70. CLINICAL STATEMENTS AND GUIDELINES S7.2.1-9. Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in advanced heart failure: high risk of sudden death regardless of ori- gin of syncope. J Am Coll Cardiol. 1993;21:110 6. S7.2.1-10. Olshansky B, Poole JE, Johnson G, et al. Syncope predicts the out- come of cardiomyopathy patients: analysis of the SCD-HeFT study. J Am Coll Cardiol. 2008;51:1277 82. S7.2.1-11. Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk car- diomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inap- propriate therapy (MADIT-RIT) study. Circulation. 2014;129:545 52. S7.2.1-12. Piccini JP, Berger JS, O Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245 53. S7.2.1-13. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar- macological interventions for prevention of sudden cardiac death. Cochrane Database Syst Rev. 2015;12:CD008093. S7.2.1-14. Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhyth- mia inducibility predicts subsequent ICD activation in nonisch- emic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009;32:755 61. S7.2.1-15. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stim- ulation. Circ Arrhythm Electrophysiol. 2013;6:504 12. S7.2.1-16. Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electro- physiological studies to predict arrhythmic events. World J Cardiol. 2015;7:344 50. S7.2.1-17. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/ or left ventricular dysfunction may be associated with excess mortal- ity. Am Heart J. 2008;155:87 93. 7.2.2. Primary Prevention of SCD in Patients With NICM S7.2.2-1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S7.2.2-2. B nsch D, Antz M, Boczor S, et al. Primary prevention of sud- den cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453 8. S7.2.2-3. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140 50. S7.2.2-4. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardio- myopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874 9. S7.2.2-5. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implan- tation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151 8. S7.2.2-6. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic non- sustained ventricular tachycardia AMIOVIRT. J Am Coll Cardiol. 2003;41:1707 12. S7.2.2-7. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.2.2-8. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250 60. S7.2.2-9. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79 83. S7.2.2-10. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation car- riers: a European cohort study. J Am Coll Cardiol. 2012;59: 493 500. S7.2.2-11. K ber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221 30. S7.2.2-12. Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention implantable cardioverter defibillators in patients with nonischemic cardiomyopathy: a meta-analysis. JAMA Cardiol. 2017;2:685 8. S7.2.2-13. Golwala H, Bajaj NS, Arora G, et al. Implantable cardioverter-defi- brillator for nonischemic cardiomyopathy: an updated meta-analy- sis. Circulation. 2017;135:201 3. 7.2.3. Treatment of Recurrent VA in Patients With NICM S7.2.3-1. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta- blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165 71. S7.2.3-2. Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter abla- tion of ventricular tachycardia in dilated nonischemic cardiomy- opathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129:728 36. S7.2.3-3. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997 2007. S7.2.3-4. Piers SR, Tao Q, Tvan Huls van Taxis CF, et al. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6:875 83. S7.2.3-5. Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramu- ral scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2013;6:891 7. S7.2.3-6. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407 13. 7.3. Arrhythmogenic Right Ventricular Cardiomyopathy S7.3-1. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet. 2015;8:437 46. S7.3-2. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013;61:1945 8. S7.3-3. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhyth- mogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123:2701 9. S7.3-4. te Riele AS, James CA, Groeneweg JA, et al. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomy- opathy. Eur Heart J. 2016;37:755 63. S7.3-5. Liu T, Pursnani A, Sharma UC, et al. Effect of the 2010 task force criteria on reclassification of cardiovascular magnetic resonance criteria for arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:47. S7.3-6. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmo- genic right ventricular cardiomyopathy/dysplasia: proposed modifi- cation of the task force criteria. Circulation. 2010;121:1533 41. S7.3-7. te Riele AS, Bhonsale A, James CA, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratifica- tion of arrhythmogenic right ventricular dysplasia/cardiomyopa- thy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1761 9. S7.3-8. Vermes E, Strohm O, Otmani A, et al. Impact of the revision of arrhythmogenic right ventricular cardiomyopathy/dysplasia task force criteria on its prevalence by CMR criteria. JACC Cardiovasc Imag. 2011;4:282 7. S7.3-9. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy under- going implantable cardioverter-defibrillator implantation for pri- mary prevention. J Am Coll Cardiol. 2011;58:1485 96. CLINICAL STATEMENTS AND GUIDELINES S7.3-10. Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defi- brillator in patients with arrhythmogenic right ventricular cardiomy- opathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122:1144 52. S7.3-11. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Circulation. 2015;132:441 53. S7.3-12. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, charac- teristics, and treatment. J Am Coll Cardiol. 2014;64:119 25. S7.3-13. Piccini JP, Dalal D, Roguin A, et al. Predictors of appropriate implant- able defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2005;2:1188 94. S7.3-14. Marcus FI, Zareba W, Calkins H, et al. Arrhythmogenic right ventric- ular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm. 2009;6:984 92. S7.3-15. Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhyth- mic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009;54:609 15. S7.3-16. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopatho- logic manifestations of arrhythmogenic right ventricular car- diomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512 20. S7.3-17. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age- related penetrance and arrhythmic risk in arrhythmogenic right ven- tricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62:1290 7. S7.3-18. Ruwald AC, Marcus F, Estes NA 3rd, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2015;36:1735 43. S7.3-19. Saberniak J, Hasselberg NE, Borgquist R, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail. 2014;16:1337 44. S7.3-20. Sawant AC, Bhonsale A, te Riele AS, et al. Exercise has a dispropor- tionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal muta- tions. J Am Heart Assoc. 2014;3:e001471. S7.3-21. Sawant AC, te Riele AS, Tichnell C, et al. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016;13:199 207. S7.3-22. Bhonsale A, Groeneweg JA, James CA, et al. Impact of geno- type on clinical course in arrhythmogenic right ventricular dys- plasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36:847 55. S7.3-23. Bhonsale A, James CA, Tichnell C, et al. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associ- ated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013;6:569 78. S7.3-24. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evalua- tion of cardiomyopathy a Heart Failure Society of America practice guideline. J Card Fail. 2009;15:83 97. S7.3-25. Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associ- ated mutations from background genetic noise. J Am Coll Cardiol. 2011;57:2317 27. S7.3-26. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6:533 42. S7.3-27. Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dyspla- sia/cardiomyopathy. Heart Rhythm. 2015;12:716 25. S7.3-28. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ven- tricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. 2012;5:499 505. S7.3-29. Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter abla- tion of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007;50:432 40. S7.3-30. Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and out- come with epicardial ablation of ventricular tachycardia in arrhyth- mogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2009;120:366 75. S7.3-31. Bai R, Di BL, Shivkumar K, et al. Ablation of ventricular arrhyth- mias in arrhythmogenic right ventricular dysplasia/cardiomyopa- thy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol. 2011;4: 478 85. S7.3-32. Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endo- cardial and epicardial catheter ablation in arrhythmogenic right ven- tricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol. 2012;5:111 21. S7.3-33. Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8:1413 21. S7.3-34. Choudhary N, Tompkins C, Polonsky B, et al. Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: findings from the North American ARVC Registry. J Cardiovasc Electrophysiol. 2016;27:555 62. S7.3-35. Kamath GS, Zareba W, Delaney J, et al. Value of the signal-averaged electrocardiogram in arrhythmogenic right ventricular cardiomyopa- thy/dysplasia. Heart Rhythm. 2011;8:256 62. S7.3-36. Saguner AM, Medeiros-Domingo A, Schwyzer MA, et al. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2013;111:250 7. S7.3-37. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhyth- mogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175 87. S7.3-38. Te Riele AS, James CA, Philips B, et al. Mutation-positive arrhyth- mogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol. 2013;24: 1311 20. S7.3-39. Rastegar N, Zimmerman SL, Te Riele AS, et al. Spectrum of biven- tricular involvement on cmr among carriers of arvd/c-associated mutations. JACC Cardiovasc Imag. 2015;8:863 4. S7.3-40. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic charac- terization of families with arrhythmogenic right ventricular dyspla- sia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710 20. S7.3-41. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricu- lar dysplasia: a United States experience. Circulation. 2005;112: 3823 32. S7.3-42. Brun F, Groeneweg JA, Gear K, et al. Risk stratification in arrhythmic right ventricular cardiomyopathy without implantable cardioverter- defibrillators. JACC Clin Electrophysiol. 2016;2:558 64. S7.3-43. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084 91. S7.3-44. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493 500. S7.3-45. Cox MG, van der Zwaag PA, van der Werf C, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmo- some mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/car- diomyopathy genotype-phenotype follow-up study. Circulation. 2011;123:2690 700. S7.3-46. Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electro- physiologic testing in risk stratification for sudden cardiac death. J Invasive Cardiol. 2001;13:758 62. S7.3-47. Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1998;21:299 302. S7.3-48. Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhyth- mic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29 37. CLINICAL STATEMENTS AND GUIDELINES 7.4. Hypertrophic Cardiomyopathy S7.4-1. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:1596 601. S7.4-2. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertro- phic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212 8. S7.4-3. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420 4. S7.4-4. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic car- diomyopathy. Eur Heart J. 2006;27:1933 41. S7.4-5. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 1998;82:774 8. S7.4-6. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defi- brillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405 12. S7.4-7. O Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010 20. S7.4-8. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119:1703 10. S7.4-9. O Mahony C, Lambiase PD, Quarta G, et al. The long-term sur- vival and the risks and benefits of implantable cardioverter defi- brillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116 25. S7.4-10. Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter- defibrillator in patients with hypertrophic cardiomyopathy: effi- cacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol. 2010;21:883 9. S7.4-11. Adabag AS, Kuskowski MA, Maron BJ. Determinants for clini- cal diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:1507 11. S7.4-12. Afonso LC, Bernal J, Bax JJ, et al. Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technolo- gies. JACC Cardiovasc Imag. 2008;1:787 800. S7.4-13. Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol. 2010;55:1444 53. S7.4-14. Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15:972 7. S7.4-15. Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing. Circulation. 2013;127:48 54. S7.4-16. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two- dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699 708. S7.4-17. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic car- diomyopathy. Clinical spectrum and treatment. Circulation. 1995;92:1680 92. S7.4-18. Christiaans I, Birnie E, van Langen IM, et al. The yield of risk strati- fication for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predic- tive screening. Eur Heart J. 2010;31:842 8. S7.4-19. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic car- diomyopathy. Mayo Clin Proc. 2008;83:630 8. S7.4-20. Christiaans I, van Langen IM, Birnie E, et al. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients perspective. Am J Med Genet. 2009 149a 1444 51. S7.4-21. Hamang A, Eide GE, Rokne B, et al. Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long QT syndrome or hypertrophic cardiomyopathy: a one year follow-up. J Genet Counsel. 2012;21:72 84. S7.4-22. Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype- based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89:727 37. S7.4-23. Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr. 2006;19:788 95. S7.4-24. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopa- thy. N Engl J Med. 2000;342:1778 85. S7.4-25. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:1481 6. S7.4-26. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardio- verter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365 73. S7.4-27. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricu- lar tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42:873 9. S7.4-28. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of sys- temic blood pressure response during exercise in a community- based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044 51. S7.4-29. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assess- ment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987 91. S7.4-30. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ven- tricular tachycardia. Br Heart J. 1985;53:412 6. S7.4-31. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hyper- trophic cardiomyopathy. Heart. 2007;93:708 10. S7.4-32. Kuck KH, Kunze KP, Schluter M, et al. Programmed electrical stimu- lation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J. 1988;9:177 85. S7.4-33. Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1998;21:299 302. S7.4-34. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age- dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a compre- hensive outpatient perspective. J Am Coll Cardiol. 2002;39:2042 8. S7.4-35. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta- analysis of genotype-phenotype associations in patients with hyper- trophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99:1800 11. S7.4-36. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopa- thy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2011;124:783 831. S7.4-37. Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gado- linium enhancement in clinical outcomes for hypertrophic cardio- myopathy. JACC Cardiovasc Imaging. 2012;5:370 7. S7.4-38. O Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867 74. S7.4-39. Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast- enhanced magnetic resonance imaging in patients with hypertro- phic cardiomyopathy. Circ Heart Fail. 2010;3:51 8. S7.4-40. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratifica- tion and management. J Am Coll Cardiol. 2017;69:761 73. S7.4-41. Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013;127:585 93. S7.4-42. Francia P, Adduci C, Palano F, et al. Eligibility for the subcutaneous implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:893 9. CLINICAL STATEMENTS AND GUIDELINES S7.4-43. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J. 2011;32:1161 70. S7.4-44. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358:1899 908. S7.4-45. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248 57. S7.4-46. Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J. 2010;31:1551 3. S7.4-47. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol. 2011;107:604 8. S7.4-48. Ingles J, Doolan A, Chiu C, et al. Compound and double muta- tions in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59. S7.4-49. Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753 60. S7.4-50. O Mahony C, Jichi F, Monserrat L, et al. Inverted U-shaped relation between the risk of sudden cardiac death and maximal left ventricu- lar wall thickness in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9:e003818. S7.4-51. Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electro- physiologic testing in risk stratification for sudden cardiac death. J Invasive Cardiol. 2001;13:758 62. S7.4-52. Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: one gene but many phenotypes. Am J Cardiol. 2014;113:1772 3. S7.4-53. Ho CY, Cirino AL, Lakdawala NK, et al. Evolution of hypertro- phic cardiomyopathy in sarcomere mutation carriers. Heart. 2016;102:1805 12. S7.4-54. Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardio- vascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561 7. S7.4-55. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertro- phic cardiomyopathy. Circulation. 2008;118:1541 9. S7.4-56. Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of mid- ventricular obstruction in patients with hypertrophic cardiomyopa- thy. J Am Coll Cardiol. 2011;57:2346 55. S7.5-1. Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term progno- sis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J. 2002;66:133 44. S7.5-2. Maleszewski JJ, Orellana VM, Hodge DO, et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015;115:1733 8. S7.5-3. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860 6. S7.5-4. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15 22. S7.5-5. Friman G, Wesslen L, Fohlman J, et al. The epidemiology of infec- tious myocarditis, lymphocytic myocarditis and dilated cardiomy- opathy. Eur Heart J. 1995:16 suppl O:36 41. S7.5-6. Hufnagel G, Pankuweit S, Richter A, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz. 2000;25:279 85. S7.5-7. Winkel E, Parrillo J. Myocarditis. Curr Treat Options. Cardiovasc Med. 2002;4:455 66. S7.5-8. Zawadowski GM, Klarich KW, Moder KG, et al. A contemporary case series of lupus myocarditis. Lupus. 2012;21:1378 84. S7.5-9. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowl- edge on aetiology, diagnosis, management, and therapy of myo- carditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636 2648d. S7.5-10. Elamm C, Fairweather D, Cooper LT, Pathogenesis and diagnosis of myocarditis. Heart. 2012;98:835 40. S7.5-11. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738 47. S7.5-12. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term out- come of fulminant myocarditis as compared with acute (nonfulmi- nant) myocarditis. N Engl J Med. 2000;342:690 5. S7.5-13. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091 100. S7.5-14. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639 48. S7.5-15. Tubman TR, Craig B, Mulholland HC. Ventricular tachycardia asso- ciated with Coxsackie B4 virus infection. Acta Paediatr Scand. 1990;79:572 5. S7.5-16. Tai YT, Lau CP, Fong PC, et al. Incessant automatic ventricular tachy- cardia complicating acute coxsackie B myocarditis. Cardiology. 1992;80:339 44. S7.5-17. Dhar KL, Adlakha A, Phillip PJ. Recurrent seizures and syncope, ventricular arrhythmias with reversible prolonged Q-Tc interval in typhoid myocarditis. J Indian Med Assoc. 1987;85:336 7. S7.5-18. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803 69. S7.5-19. Cooper LT Jr, Elamm C, Giant cell myocarditis. Diagnosis and treat- ment. Herz. 2012;37:632 6. S7.5-20. Milei J, Grana D, Fernandez AG, et al. Cardiac involvement in acquired immunodeficiency syndrome a review to push action. The Committee for the Study of Cardiac Involvement in AIDS. Clin Cardiol. 1998;21:465 72. S7.5-21. Yunis NA, Stone VE, Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:145 54. S7.5-22. Huang CN, Yu HH, Chiu SN, et al. Acute myocarditis and ventricular fibrillation as initial presentation of pediatric systemic lupus erythe- matosus. Rheumatol Int. 2013;33:1093 6. S7.5-23. Rassi A Jr, Rassi A, Little WC, Chagas heart disease. Clin Cardiol. 2000;23:883 9. S7.5-24. Muratore C, Rabinovich R, Iglesias R, et al. Implantable cardioverter defibrillators in patients with Chagas disease: are they different from patients with coronary disease? Pacing Clin Electrophysiol. 1997;20:194 7. S7.5-25. d Avila A, Splinter R, Svenson RH, et al. New perspectives on cath- eter-based ablation of ventricular tachycardia complicating Chagas disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas VT. J Interv Card Electrophysiol. 2002;7:23 38. S7.5-26. Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123. S7.5-27. Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol. 2004;27:4 9. S7.5-28. Cooper LT, Okura Y. Idiopathic giant cell myocarditis. Curr Treat Options Cardiovasc Med. 2001;3:463 7. 7.6. Cardiac Sarcoidosis S7.6-1. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epi- demiology, characteristics, and outcome over 25 years in a nation- wide study. Circulation. 2015;131:624 32. S7.6-2. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long- term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006 10. S7.6-3. Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implant- able cardiac defibrillators for treatment of ventricular arrhyth- mias in patients with cardiac sarcoidosis. Europace. 2013;15: 347 54. CLINICAL STATEMENTS AND GUIDELINES S7.6-4. Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electro- physiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2014;25:171 6. S7.6-5. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defi- brillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925 9. S7.6-6. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016;10:411 20. S7.6-7. 